Differential radiation protection of salivary glands versus tumor by tempol with accompanying tissue assessment of tempol by magnetic resonance Imaging

被引:97
作者
Cotrim, Ana P.
Hyodo, Fuminori
Matsumoto, Ken-Ichiro
Sowers, Anastasia L.
Cook, John A.
Baum, Bruce J.
Krishna, Murali C.
Mitchell, James B.
机构
[1] Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Radiat Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-07-0662
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The nitroxide free radical,Tempol, was evaluated for potential differential radiation protection of salivary glands and tumor using fractionated radiation. Mechanistic information was explored by monitoring the presence and bioreduction of Tempol in both tissues noninvasively by magnetic resonance imaging (MRI). Experimental Design: Female C3H mice were immobilized using custom-made Lucite jigs for localized irradiation (five daily fractions) either to the oral cavity or tumor-bearing leg. Tempol (275 mg/kg) was administered (i.p.) 10 min before each radiation fraction. Salivary gland damage was assessed 8 weeks after radiation by measuring pilocarpine-mediated saliva output. Tumor growth was assessed by standard radiation regrowth methods. Dynamic T-1-weighted magnetic resonance scans were acquired before and after Tempol injection using a 4.7Tanimal MRI instrument. Results: Tempol treatment was found to protect salivary glands significantly against radiation damage ( similar to 60% improvement); whereas no tumor protection was observed. Intracellular reduction of Tempol to the nonradioprotective hydroxylamine as assessed by MRI was 2-fold faster in tumor compared with salivary glands or muscle. Conclusions: Tempol provided salivary gland radioprotection and did not protect tumor, consistent with the hypothesis that differential radioprotection by Tempol resides in faster reduction to the nonradioprotective hydroxylamine in tumor compared with normal tissues. The unique paramagnetic properties of Tempol afforded noninvasive MRI monitoring of dynamic changes of Tempol levels in tissue to support the finding. These data support further development and consideration of Tempol for human clinical trials as a selective protector against radiation- induced salivary gland damage.
引用
收藏
页码:4928 / 4933
页数:6
相关论文
共 33 条
[1]   Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy [J].
Andreassen, CN ;
Gran, C ;
Lindegaard, JC .
SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (01) :62-72
[2]   Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma [J].
Bourhis, J ;
Rosine, D .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :61-62
[3]   Does amifostine have a role in chemoradiation treatment? [J].
Brizel, DM .
LANCET ONCOLOGY, 2003, 4 (06) :378-381
[4]   Tumor microenvironment and the response to anticancer therapy [J].
Brown, JM .
CANCER BIOLOGY & THERAPY, 2002, 1 (05) :453-458
[5]   Oxidative stress, redox, and the tumor microenvironment [J].
Cook, JA ;
Gius, D ;
Wink, DA ;
Krishna, MC ;
Russo, A ;
Mitchell, JB .
SEMINARS IN RADIATION ONCOLOGY, 2004, 14 (03) :259-266
[6]  
COOK JA, 1991, CANCER RES, V51, P4287
[7]   Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model [J].
Cotrim, AP ;
Sowers, AL ;
Lodde, BM ;
Vitolo, JM ;
Kingman, A ;
Russo, A ;
Mitchel, JB ;
Baum, BJ .
CLINICAL CANCER RESEARCH, 2005, 11 (20) :7564-7568
[8]  
Cuscela D, 1996, Cancer J Sci Am, V2, P273
[9]   The radiobiology of prostate cancer including new aspects of fractionatedradiotherapy [J].
Fowler, JF .
ACTA ONCOLOGICA, 2005, 44 (03) :265-276
[10]   Study of in vitro and in vivo effects of the piperidine nitroxide Tempol -: a potential new therapeutic agent for gliomas [J].
Gariboldi, MB ;
Ravizza, R ;
Petterino, C ;
Castagnaro, M ;
Finocchiaro, G ;
Monti, E .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :829-837